Joel N Blankson
Overview
Explore the profile of Joel N Blankson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
5680
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karaba A, Xue J, Johnston T, Traut C, Dalrymple L, Kossmann R, et al.
Kidney Int Rep
. 2025 Feb;
10(2):406-415.
PMID: 39990910
Introduction: Individuals receiving hemodialysis (HD) are at risk for severe COVID-19 and have attenuated responses to COVID-19 vaccines. Evolution of immunity and risk for subsequent infection with additional vaccinations and...
2.
Sop J, Beckey T, Jones J, Hansoti B, Gebo K, Blankson J
Lancet Microbe
. 2025 Feb;
:101084.
PMID: 39919772
No abstract available.
3.
Lee J, Sachithanandham J, Lee J, Shapiro J, Li M, Sitaris I, et al.
Microbiol Spectr
. 2025 Jan;
13(3):e0219024.
PMID: 39887251
Solid organ transplant recipients (SOTRs) suffer more frequent and more severe infections due to their compromised immune responses resulting from immunosuppressive treatments designed to prevent organ rejection. Pharmacological immunosuppression can...
4.
Griffith D, Fall A, Carter M, Traut C, Sop J, Hansoti B, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae549.
PMID: 39371365
We present a case of mpox recurrence in a transgender woman with AIDS. Her recurrent lesions required several courses of antiviral therapy over a 5-month period and her monkeypox viral...
5.
Lee J, Sachithanandham J, Lee J, Shapiro J, Li M, Sitaris I, et al.
bioRxiv
. 2024 Sep;
PMID: 39282433
Importance: This study addresses the challenges faced by kidney transplant recipients (KTRs) in mounting effective immune responses against COVID-19. By evaluating the antibody responses to a third dose of monovalent...
6.
7.
Hunt J, Jones J, Gebo K, Hansoti B, Traut C, Hamill M, et al.
J Virol Methods
. 2024 Aug;
329:115004.
PMID: 39127186
Background: Since July 23, 2022, global mpox cases reached 92,546, with over 31,000 in the United States. Asymptomatic carriage is a critical mechanism influencing the global dissemination of mpox. Seroprevalence...
8.
Sop J, Traut C, Dykema A, Hunt J, Beckey T, Basseth C, et al.
Cell Rep Med
. 2024 Feb;
5(3):101442.
PMID: 38423018
Bivalent COVID vaccines containing mRNA for ancestral and Omicron BA.5 spike proteins do not induce stronger T cell responses to Omicron BA.5 spike proteins than monovalent vaccines that contain only...
9.
Karaba A, Morgenlander W, Johnston T, Hage C, Pekosz A, Durand C, et al.
J Infect Dis
. 2023 Nov;
229(5):1366-1371.
PMID: 38019656
Kidney transplant recipients (KTRs) develop decreased antibody titers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared to healthy controls (HCs), but whether KTRs generate antibodies against key epitopes...
10.
Kwaa A, Blankson J
Annu Rev Immunol
. 2023 Oct;
42(1):21-33.
PMID: 37827174
Elite controllers are a heterogeneous group of people living with HIV who control viral replication without antiretroviral therapy. There is substantial evidence that at least some elite controllers are infected...